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Anti TNFalpha immunomodulators and susceptibility to infectious diseases 
 
Abstract 
Tumor necrosis factor-α is a pleiotropic cytokine involved in a variety of immunological processes. It 
plays a major role in protective immunity, intervening in the control of infections, especially in the 
defense against intracellular microorganisms. However, it can also be implicated in a number of 
pathological processes, as is the case of autoimmune diseases.   
The introduction of anti-TNF-α biological therapy constituted a major progress in the treatment of many 
autoimmune diseases. However, as the usage of these drugs expanded several reports of infections have 
been increasingly reported in patients taking these medications. Nonetheless, the current evidence does 
not offer undoubtable proof of a causal relationship between pharmacologic TNF-α’s inactivation and the 
emergence of different infections. 
In this work, the authors review TNF-α’s general biological functions and mechanisms of action, and 
summarize the evidences found in literature regarding the role and importance of TNF in the immune 
defense against different microorganisms, particularly Mycobacterium tuberculosis, Streptococcus 
pneumoniae, Listeria monocitogenis, Histoplasma capsulatum, Candida, Leishmania, Hepatitis B virus 
and Herpes simplex virus. 
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Introduction 
Tumor Necrosis Factor-α (TNF-α) is a cytokine with multiple effects of importance in inflammation 
and immune functions.[1] In fact, it has been found to contribute to the immune defense against several 
pathogens, including virus (e.g. Herpes virus, Hepatitis virus), bacteria (such as mycobacteria and 
intracellular bacteria, like Listeria), fungi (e.g. Candida, Aspergillus, Blastomyces and Histoplasma) and 
parasites.[2] Moreover, due to its strong pro-inflammatory and immunostimulatory activities, TNF is, in 
general, an important mediator of progression of many autoimmune diseases, including rheumatoid 
arthritis and inflammatory bowel disease; significant clinical improvement can be achieved in these 
contexts when patients are treated with TNF-α neutralizing agents.[3] 
Development of TNF inhibitors and its introduction in clinical practice was a significant milestone for 
the treatment of selected autoimmune diseases. Currently, there are five approved anti-TNFα agents, 
including infliximab, etanercept, adalimumab, certolizumab pegol and golimumab.[4,5] All of the 
approved anti-TNF agents, except for eternacept, are full-length bivalent IgG monoclonal antibodies or 
monovalent Fab antibody fragments. Etanercept is a genetically engineered fusion protein consisting of 
an Fc fragment of human IgG1 fused to a dimer of the extracellular part of human TNF-receptor (TNFR) 
2. Infliximab is a chimeric protein, 25% of which are constituted by mouse-derived amino acids, with 
human-derived amino acids forming the remaining 75%. Certolizumab is a humanized protein, containing 
amino acid sequences derived from a mouse’s anti-TNF monoclonal antibody, inserted into human VH 
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and VL domains; the hinge region of certolizumab is covalently linked to polyethileno glycol, which 
ensures better solubility and half-life prolongation; additionally, since it is a Fab fragment and has no Fc 
region, it lacks effector functions. Adalimumab and golimumab are fully human monoclonal antibodies.  
TNF inhibitors revolutionized the treatment of many autoimmune conditions, being especially 
advantageous to the patients resistant to first-line treatments. Due to their ability to decrease the 
inflammatory parameters associated with the autoimmune disease, anti-TNF drugs allowed these patients, 
who otherwise would have a more active disease, to have a beter quality of life. 
However, ever since the introduction of anti-TNF drugs, several reports have claimed an increased 
incidence of infectious diseases in these patients, suggesting a probable association of this findings to the 
therapy in question; among the reported, are included opportunist infections, such as Mycobacterium 
tuberculosis, Listeria monocytogenes, Leishmania, Toxoplasma gondii, Histoplasma capsulatum, 
Candida and Aspergillus infections. [2,3,6]  
Therefore, in order to prevent these secondary infections, it is essential to improve our knowledge of 
TNF-α’s actions and the mechanisms through which it influences the immune responses to different 
pathogens. Several experimental studies have already been performed in this area, mostly using animal 
and in vitro models, in order to understand the link between TNF and infection. This review of the 
literature aims to comprehensibly summarize the mechanisms through which TNF contributes to the 
immunological defense against different pathogens, as well as to revise the consequences of its inhibition 
using biologic anti-TNF drugs.  
 
Overview of TNF’s functions 
TNF is a pleiotropic factor synthetized mainly by activated macrophages in response to various 
stimuli (bacteria, viruses, complement factors, ischemia, hypoxia, injury and cytokines, such as IL-1, IL-
17, TNF, GM-CSF or IFN-ƴ)[7], but also by a broad variety of other tissues, including lymphoid cells, 
mast cells, endothelial cells, fibroblasts and neuronal tissue. [7,8,3] It functions as a key regulator of 
leukocyte trafficking and its effects include increased vascular permeability, migration and maturation of 
dendritic cells, antigen processing, activation of macrophages and nitric oxide production, induction of its 
own secretion and upregulation of other molecules, such as: proinflammatory cytokines (e.g., INF-ƴ in T-
lymphocytes and NK-cells), chemokines, prostaglandins, adhesion molecules and major 
histocompatibility complex molecules. [9,10] The proteins induced by TNF include IL-6, IL-8, GM-CSF, 
M-CSF, plasminogen’s activator inhibitor and platelet activating factor; among new antigens appearing 
on the endothelial membrane are the adhesion molecule E-selectine, membrane-bound IL-1 and 
enhancement of lymphocyte adhesion molecule ICAM-1 and VCAM-1; the enzymes inducible nitric 
oxide synthase (iNOS) and COX-2 are also activated.[11,12]  
TNF directs leucocyte movement through several mechanisms, including its action on the vascular 
endothelium and its ability to establish gradients for chemokines, such as CCL2 (MCP1), CCL3 (MIP1a), 
CCL4 (MIP1b), CCL5 (RANTES), CXCL10, and CXCL13.[13] Furthermore, its signal results in 
leukocytes’ cytoskeletal re-organization, filopodium formation and macropinocitosis, ultimately enabling 
the process of leukocyte migration. [9]  
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TNF has a cytotoxic action and causes necrosis and lysis of the target cell; nonetheless, this cytokine 
can also induce cell death through other pathways. In fact, in some cell types, TNF’s action leads to 
apoptosis. The induction of apoptosis by TNF-α is mainly mediated by activation of TNFR1, which 
results in activation of pro-caspase 8. [14,3] Additionally, on a number of cells, especially primary 
fibroblasts, TNF exerts a mitogenic activity, presumably through induction of proteins that promote cell 
cycle. [14,12] IL-10 is induced by TNF-α and, in turn, also inhibits its synthesis, therefore being involved 
in a negative feedback loop.[4] 
There are two biological forms of TNF: transmembrane-TNF and soluble-TNF; both forms function 
physiologically by interacting with the TNF-receptors 1 and 2. Membrane-bound TNF may be cleaved by 
tumor necrosis factor alpha-converting enzyme, a matrix metalloprotease, which leads to the release of 
soluble TNF.[8] TNF-α binds as homotrimers to TNF receptor 1 (p55) and TNF receptor 2 (p75). [15] 
TNF-receptors are present on nearly all cell types, with a few exceptions (for example, erythrocytes); 
TNFR1 seems to be ubiquitous and occurs, among others, on epithelial cells and fibroblasts; on the other 
hand, TNFR2 seems to be more restricted to immune system cells (for example, it is strongly expressed 
upon T-cells’ induction). [12] When TNF binds to TNFR1, the receptor’s conformation is changed in 
order that its death domain can interact with TNFR-associated factor containing death domains 
(TRADD), which in turn recruit TNFR-associated factors (TRAFs), including TRAF2 and TRAF5, as 
well as the cellular inhibitor of apoptosis proteins 1 and 2 (c-IAP1/2), in order to form the TNF-receptor 
signaling complex (TNF-RSC). Subsequent steps lead to translocation of NF-kB to the nucleus, where it 
initiates the transcription of more than 200 NF-kB-dependent genes, including cell-survival genes, pro-
inflammatory cytokines, chemokines, growth-factors and TNF-α itself; TNF signalling also activates a 
heterodimer called Activation Protein 1 (AP-1), which is a critical transcription factor itself and has 
similar functions to NF-kB. [14,3] TNFR2 does not contain a death domain, but is able to form a complex 
with TRAF2 and TRAF5 upon stimulation with TNF, leading to activation of NF-kB and AP-1. [14,3] 
Therefore, there is a complex interaction and cross-talk between TNFR1 and TNFR2 signaling.[16] 
 
TNF and granuloma formation/ defense against Micobacterium tuberculosis 
TNF is believed to be essential in the maintenance of granulomas.[17,18] In fact, as both experimental 
and observational studies have shown, its downregulation could lead to an increased susceptibility to 
granulomatous infections, such as tuberculosis, histoplasmosis or listeriosis. [17,18]  
TNF has been shown to be fundamentally involved in cellular immunity against intracellular 
pathogens, as exemplified by its role in regulating immunity against mycobacterium species, particularly 
in tuberculosis by Micobacterium tuberculosis (M. tuberculosis). [19] 
The first contact of the host with M. tuberculosis can have three possible outcomes: the person 
becomes infected and develops symptoms of the disease (primary infection); the immune system is 
capable of controlling the bacteria, eliminating it from the host; the immune system can partially control 
the pathogen and M. tuberculosis becomes dormant (latent infection), although symptoms may possibly 
develop sometime in the future (secondary infection). [20] Not everyone with a latent infection will 
manifest the clinical disease, and only about 10% of them will have a reactivation of tuberculosis. [20]  
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Infection by M. tuberculosis results in the recruitment of host macrophages, which phagocyte the 
bacteria and then transit into deeper tissues. There, the infected macrophages initiate the inflammatory 
response, which includes production of TNF, IL-12, IL-1, IL-6 and various chemokines [21], along with 
recruitment of additional macrophages and other immune cells (e.g. monocytes, neutrophils and dendritic 
cells). [22] At this point, the bacilli are likely taken up by dendritic cells, which then traffic to lung-
draining lymph nodes and prime naive T-cells. [22] Effector T-cells move to the lungs to help forming 
tightly aggregated immune structures, called granulomas; this is one of the TNF-α major 
functions.[16,20] On the effector side, TNF supports apoptosis of infected macrophages, activated 
cytotoxic T-cell are able to kill the bacilli through phagocytosis, and there is an induction of reactive 
nitrogen intermediates’ (RNI) production.[16,13] 
The downregulation of the immune system can play a part in the M. tuberculosis’s reactivation, as 
probably does the inhibitory action of an array of cytokines essential in tuberculosis control. Patients 
taking anti-TNF drugs have increased risk of reactivating latent tuberculosis or developing a tuberculosis 
infection de novo. [23]  
Early experimental works evidenced TNF-α’s importance in the defense against Mycobacterium 
infection by showing that experimental models of TNF’s inhibition lead to greater susceptibility to 
infection by this pathogen. Mice lacking TNF-α have been shown to have a much higher susceptibility to 
M. tuberculosis and to succumb to infection, with higher loads of bacteria, when compared to wild-type 
mice.[24,25] Furthermore, the cellular recruitment has been shown to be significantly delayed in the 
TNF-negative mice, with higher inflammatory cell levels and appearance of granulomas at a later time 
during the infectious process, in comparison to wild-type mice.[25,24] The induction of chemokines 
(MIP-1bβ, MIP-2, MCP-1 and eotaxin) has also been shown to follow a similar pattern: at first it is 
delayed in mice lacking TNF, but after some time it peaks, reaching higher levels than in wild-type mice. 
[25]  
Nevertheless, although some experimental studies [24,25] showed that formation of granulomas in 
TNF-depleted mice occurs in equal numbers to control mice, their characteristics differed from those in 
the latter group: the cells did not form tight clusters; and the granulomas were less organized and lacked 
differentiated cells (e.g. epithelioid cells). Furthermore, some studies found that granulomas formed 
without TNF signaling displayed a larger size, which was thought to be caused by an increase in 
macrophages, possibly lead by the higher bacterial burden observed in this context. [26] 
Other in vivo studies that followed have led to the prevailing view that TNF is responsible for 
granuloma formation and maintenance. [26] This hypothesis is consistent with its well-known role in 
orchestrating macrophage trafficking and leukocytes movement during inflammation. However, 
subsequent experimentation showed that TNF is likely unnecessary for the formation of granulomas; 
additionally, TNF’s absence was shown to be responsible for the loss of previously formed granuloma, as 
it resulted in increased granuloma expansion and accelerated necrosis of participating macrophages due to 
higher intracellular bacterial burdens.[26]  
There have also been studies evaluating the production of nitric oxide and RNI, considering this is a 
known mechanism by which macrophages control mycobacteria. [24] iNOS seems to be induced by INF-
ƴ, while TNF-α exerts a co-stimulatory activation.[20,16] When macrophages lacking TNF-receptor are 
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stimulated with TNF and IFN- ƴ, they do not evidence an increase in the production of nitric oxide, as 
opposed to wild-type macrophages that respond to this stimuli. [24] While wild-type macrophages 
produce substantial spontaneous RNI upon infection, macrophages lacking TNF-receptor do not do so in 
the absence of alternative stimulation.[24,16] Nevertheless, a few days after the beginning of infection, 
TNF-negative mice and control-mice produced almost equivalent amounts of spontaneous RNI. [24] 
Furthermore, other experimental works also found no difference in expression of iNOS or RNI between 
knock-out and control groups. [16] 
Classically, granulomas are thought to preform three basic functions: they are a structure that 
physically gathers pathogens and immune cells together, facilitating the interaction of immune cells in 
order to kill the bacteria; they form a barrier that prevents the spread of bacilli to other areas; and they 
also prevent the spreading of inflammation. [22,21] 
However, contradicting these theories, granulomas have recently been hypothesized to contribute to 
the spreading of bacteria and growth of bacterial burden.[27,26] Indeed it seems that bacillus benefit from 
this structure, which appears to work as a “shelter” until conditions are favorable for growth and 
reactivation. In fact, although a large portion of the bacilli within the granuloma can likely be killed, a 
few are able to survive and under certain conditions they may reactivate.[21] In the absence of TNF, 
studies have shown an increased death of granuloma macrophages by a non-apoptotic way, which was 
associated with a higher mycobacterial burden. Regardless of whether increased macrophage death is a 
primary or secondary effect of the loss of TNF signaling, it confers a further growth advantage to the 
bacteria by rendering them extracellular. Additionally, bacteria released from dead granuloma 
macrophages can subsequently be ingested by other macrophages, thus perpetuating the infection. [26] 
Rather than being a cytokine responsible for starting and upregulating the immune response against 
intracellular pathogens, experiments with mycobacterium have suggested that TNF is actually important 
in its downregulation; this suggests that the lack of TNF would ultimately lead to an increased Th1 
immune response, with higher levels of IFN-ƴ and IL-12. [16,28] In an experimental model of 
mycobacterial infection, it was found that TNF-deficient mice had an immune response characterized by 
expansion and activation of CD4
+
 and CD8
+
 T-cells, overproduction of IFN-ƴ and IL-12, and 
simultaneous disintegration and degradation of granuloma and lung structure.[29] TNF was concluded to 
be a critical negative regulator of cellular immunity, at least in part by suppressing T-cell proliferation 
during intracellular mycobacterial infection. It became clear that most of the pathology stemmed not from 
the increased number of mycobacteria but most likely from a deregulation of the immune response to 
infection.[30]  
Regarding latent infection, some studies evidenced that TNF-α is expressed in Mycobacterium 
tuberculosis infected tissues throughout the quiescent phase of infection. [31] TNF has not only been 
involved in response to acute mycobacterium infection, but has also been shown to play a role in chronic 
persistent tuberculosis and its reactivation.[31] On TNF-α-deficient mice with chronic persistent 
tuberculosis, receiving anti-tuberculosis drugs, the drugs’ cessation resulted in a massive spontaneous 
reactivation of the infection, with necrotic pneumonia and death; contrary to that, wild-type mice 
displayed mild subclinical reactivation. [31]. Experiments using anti-TNF antibodies or soluble TNF-
receptor were able to reactivate latent infection. Disease recrudescence was associated with: moderately 
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increased bacterial burden and 100% mortality; altered levels of specific genes in the lungs (increased IL-
10 and decreased iNOS expression); and severe pulmonary infiltration of inflammatory cells. [16,31]  
 
TNF-α’s role in other bacterial infections 
Listeria monocytogenes is a facultative intracellular coccobacillus that is particularly prevalent in 
immunocompromised patients; immunity in this context is due to rapid activation of neutrophils and 
macrophages, followed by activation of specific CD4
+
 and CD8
+
 T-cells. [8] TNF has an essential 
protective role in Listeria infections, since TNF-depleted mice are unable to control the growth of 
Listeria.[8] Transmembrane TNF is sufficient to establish protective immunity against a primary low-
dose Listeria infection (despite increased hepatic inflammation); however, soluble TNF is required for 
optimal control of cellular inflammation and resistance to a primary high-dose infection; moreover, in the 
case of a high-dose infection and lack of soluble TNF, a delay in leukocytes infiltration and, more 
specifically, a delayed T-cell response, is observed. By contrast, membrane TNF alone is sufficient for 
resolution of a secondary high-dose infection and for transfer of protective immunity, from mice immune 
to Listeria to TNF-deficient mice, through memory T-cells. [8]  
Host defense against Streptococcus pneumoniae is also dependent on TNF-α’s action. In TNF-α 
knock-out mice infected with Streptococcus pneumoniae, it was observed an early and high mortality, 
along with increased bacterial counts in blood and lungs.[32] Similar observations had previously been 
made in TNF-α-depleted mice infected with a lethal Streptococcus pneumoniae strain (serotype 3).[33] In 
both these studies, the knock-out mice’s lung histopathology did not significantly differ from the control 
group’s.[32,33] On the other hand, histopathology of the knock-out mice’s spleen revealed a severe white 
pulp depletion and increased apoptosis, in comparison to wild-type mice; mice infected with a lethal 
strain showed exacerbated liver damage in the context of disseminated infection. [33] In this animal 
model, the absence of the cytokine influenced the extrapulmonary pathology to a greater extent than the 
pulmonary pathology, and sepsis and systemic organ damage were probably the cause of death in these 
animals. [32] Cases of exacerbated Legionella infection have been reported in patients taking anti-TNF 
drugs, constituting one of infectious diseases probably linked to this therapy. 
 
TNF-α’s role in viral infections 
TNF-α is also implied in the defense against virus. Viral components can be recognized by the innate 
immune system, leading to release of TNF-α; this is the case of Herpes simplex virus (HSV) type 1, when 
recognized by Toll-like receptors 2 and 3. [35] Anti-TNF therapy is frequently associated with worse 
clinical manifestations, especially in chronic infections (including latent viral infections, such as Varicella 
zoster virus or HSV, which are often reactivated in this context). [9]  One of TNF-α’s properties is its 
ability to inhibit replication of a number of RNA and DNA virus. [1,34,15] Several authors have shown 
that, when both TNF and IFN-ƴ are present simultaneously, they induce a synergistic response which 
inhibits viral-gene expression and lowers viral titers to a greater extent than treatment with each cytokine 
alone; this synergistic antiviral activity state has been shown to be effective against a diverse array of 
viruses, including HSV1, HSV2, murine Cytomegalovirus and Adenovirus. [35] HSV2’s replication is 
inhibited after co-stimulation with IFN-ƴ and TNF-α; it has been evidenced that TNF alone is unable to 
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inhibit HSV2’s replication, but rather acts to enhance IFN-ƴ activity in this context.  These cytokines act 
together by inducing indoleamine 2,3-dioxygenase, which cleaves the essential amino acid L-tryptophan 
to kyurenine, causing L-tryptophan’s availability for protein synthesis to decrease and, therefore, limiting 
HSV2’s replication.[36] Other mechanisms proposed to explain the synergic effect of these two cytokines 
in virus control include: increased TNF-receptor expression, as well as an increased binding of TNF to the 
cell surface, both occurring after exposure to INF-ƴ; and TNF-induced secretion of INF-β, which then 
acts along with INF-ƴ. [35] Treatment with TNF has been shown to prolong the survival of mice acutely 
infected with HSV [1], and decreased levels of TNF-α have been associated with HVS1 reactivation from 
latency in humans; this could possibly be explained by a shift to a Th2-immune response. [7]  
One of the most compelling evidences for an antiviral role for TNF is the demonstration that different 
virus families encode factors which target TNF-dependent activities: Adenovirus have been shown to 
encode multiple genes that can block TNF’s cytotoxic effects; several of Poxviruses encode soluble 
versions of TNF-receptors and disruption of the viral TNFR gene in Myxoma virus resulted in reduced 
virulence in vivo; overexpression of viral genes encoding homologues of death effector domains, involved 
in p55-mediated signaling, inhibited TNF-induced apoptosis, same as occurs in the genome of Molluscum 
contagiosum [37] 
In the pulmonary intersticium, Influenza virus infects macrophages and stimulates these cells to 
release a number of cytokines, including TNF-α. An experiment in vitro has shown that TNF-α has a 
dose-dependent antiviral effect in influenza virus’ replication.[1] In this study, it was demonstrated that 
TNF decreases influenza’s viral proteins, which appears to occur at an early stage of the virus’ replication 
(namely during the translation phase).[1] 
Hepatitis B can be controlled by the action of cytotoxic T-cells that target the infected hepatocytes and 
induce their death. [38,39] Moreover, cytotoxic T-cells can also control the viral infection through the 
secretion of different cytokines, namely IFN-ƴ and TNF-α. [38] These two cytokines contribute to the 
destruction of the viral genome and proteins hosted within the hepatocytes, doing so without cytolysis and 
therefore contributing to the process of virus elimination from the host hepatic cells. [40,41,38,39] These 
cytokines are also thought to be involved in the unspecific immune response that develops before T-cell 
cytotoxic response. [42,43] 
Although IFN-ƴ and cytotoxic T-cells are normally seen as the major factors responsible for the 
destruction of infected hepatocytes and viral DNA, different studies have confirmed that TNF-α plays a 
role in controlling Hepatitis B virus’ (HBV) infection in the liver. [38,40,41]  
One of TNF-α’s non-cytotoxic roles is the downregulation of HBV-nucleocapside levels in the 
cytoplasm of infected hepatocytes.[43] Additionally under TNFα’s influence, HBV-DNA levels in the 
nucleus have been shown to be decreased, which could be a result to of possible DNA translocation from 
cytoplasmic nucleocapsides into the nucleus. These effects could be mediated through the activation of 
NF-kB by TNF and the different products of the subsequent NF-kB-induced transcription[42,43] The 
HBV-nucleocapside downregulation does not appear to be mediated by a reduction in core proteins, 
suggesting that TNF does not degrade core proteins and rather compromises nucleocapside assembly 
and/or stability. [42,43] Nonetheless, the HVB-mRNA levels do not appear to be significantly influenced 
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by TNF. Therefore, HVB-mRNA reduction does not constitute a suitable cause for the diminution of DNA 
viral replication and capsid levels. [42] 
Alongside IFN-ƴ, TNF-α was also found to be responsible for the deamination of covalently closed 
circular HBV-DNA (cccDNA). Apurinic/apyrimidinic sites in the cccDNA (introduced through cleavage 
of uracils by uracil-DNA glycosylase) are recognized and digested by endonucleases, one of which, A3B 
endonuclease, was found to be upregulated in infected hepatocytes under TNF stimulation.  Furthermore, 
DNA deamination by TNF-α was found to be almost completely inhibited when this endonuclease is 
neutralized. [40]  
TNF-α may also induce a negative regulation of HBV replication in hepatocytes through another 
molecular pathway. In fact this cytokine was shown to increase the expression of p22-FLIP in cells 
infected with HBV. [41] p22-FLIP was proven to exert an antiviral effect in vitro, suppressing HBV 
replication; furthermore, its inhibition blocks the antiviral effects of TNF-α.[41] This anti-viral effect is 
thought to be mediated by the suppression of viral enhancers and copromoter (Enh 1 and Enh 11/Cp), 
which in turn occurs through the induction of their inhibitor HNF3β and reduction of their stimulator 
HNF4α.[41] 
The control of hepatitis B by TNF can be summarized to two major effects: intervention on innate and 
adaptive immunity. Due to its involvement in innate immunity, TNF-α may be responsible for the 
activation of T-cells and, therefore, the development of adaptive immunity. Confirming this effect, TNF-
α’s blockade with antibodies in the context of an HBV infection model was shown to result in an impaired 
T-cell activation. [44] In this model, the TNF inactivation also resulted in an impaired HBV clearance, 
inducing an elevation of serum HBV viral-load and a sustained HBV viral antigen expression. The 
sustained elevation of serum HBsAg and HBV-DNA levels varied in a dose-dependent response, with 
higher anti-TNF dosages also being shown to correlate with an increased T-cell exhaustion. [44] 
Furthermore, early TNF blockade led to persistent HBV clearance with enhanced T-cell exhaustion and 
maintained high HBV viral load.[44] 
These experiments confirmed that both IFN-ƴ and TNF-α are key factors in non-cytolytic inhibition of 
HBV and, most importantly, are able to trigger nuclear HBV-DNA degradation in an additive fashion, 
with IFN-ƴ playing the dominant role in this context.[41] Alternative mechanisms under TNF influence 
and yet to be discovered may be involved in HBV elimination; nevertheless, as opposed to IFN-ƴ, TNF 
does not appear to exert is effects through iNOS activity.[42] 
Cytokines other than these two have been implicated in decreasing HBV replication; IL-2, for 
example, was shown to decrease HBV replication, in part by inducing the production of TNF.[42] 
 
TNF-α’s role in fungal infections 
Histoplasma capsulatum fungus’ infection is associated with a prompt and vigorous release of TNF, 
which does not necessarily mean that TNF is implicated in the immune response against this agent. 
Nevertheless, when TNF is neutralized, this infection has a fatal outcome, with a markedly increased 
burden of Histoplasma capsulatum evidenced in different animal models, regardless of it being a primary 
or secondary infection. [2,45] Therefore, TNF-α is necessary for protection in the context of both primary 
and secondary Histoplasma infections. [45,46] In primary infections, TNF appears to be essential in the 
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first 5 days; in fact, experiments show that neutralization of TNF-α on the seventh day of infection 
dampened the host response transiently, but did not lead to uncontrolled infection. [46]  
In infected mice, T-cells were found to constitute the  largest proportion of TNF-α-producing 
cells.[46] After TNF-α’s blockade there wasn’t an alteration in the number of T-cells expressing IFN-ƴ; 
on the other hand, T-cells expressing a memory phenotype appear to be decreased in this context; 
nevertheless, the number of activated T-cells and T-cell expansion do not seem to be influenced. [46] 
During secondary infections, TNF’s blockade appears to be associated with an upregulation of IL-10 
and IL-4, both of which are known to diminish protective immunity to Histoplasma capsulatum; in 
primary infection, TNF’s blockade correlates with a decrease in nitric oxide, which may be related to the 
impaired immunity.[2,45] In both primary and secondary infections, T-cells from infected mice given 
neutralizing anti-TNF antibodies are unable to transfer protective immunity, what may be explained by an 
increase in regulatory T-cells.[46] Mice receiving anti-TNF antibodies also showed an increased 
population of CD4
+
CD25
+
 T-cells in both primary and secondary infections, an effect which was not 
otherwise demonstrated in mice lacking other important regulatory cytokines (such as IFN-ƴ and GM-
CSF), or receiving higher inoculum of Histoplasma. However, despite that, the presence of cells 
expressing natural regulatory T-cell markers didn’t differ from the control group. The population of 
CD4
+
CD25
+
 T-cells treated with anti-TNF antibodies dampened the proliferation of Histoplasma-specific 
T-cells when in presence of antigenic extract of Histoplasma in vitro, and the suppressive effect was 
reversed with anti-IL-10 antibodies; similar results were found in vivo after transferring these cells. 
Therefore, IL-10 can be mediate the dampened proliferation of Histoplasma-specific T-cells. 
Furthermore, the neutralization of CD25 (and thus CD25 expressing cells) improved the survival and 
diminished fungal burden of anti-TNF treated mice, particularly in primary infections. [47] 
Protective immunity against other fungi, such as occurs in candida infections and aspergillosis, can be 
related to TNF-α’s function. For example, when Candida albicans yeasts were treated with TNF-α in 
vitro, this cytokine lead to impaired morphological transformation to the hyphal form of the fungus, even 
at adequate CO2 conditions. To be noted that the hypha is characteristically the invasive and resistant 
form of C. albicans, and phagocytes (neutrophils and macrophages) easily ingest the yeast form and short 
filaments of Candida. [48] TNF-α synthesis is increased during fungal infection, and TNF-knock-out 
mice or mice receiving antibodies against this cytokine show diminished survival when challenged with 
C. albicans intravenously.[6] Additionally, maximal endothelial expression of VCAM-1, E-selectin 
(leukocyte adhesion molecules) and IL-8 (neutrophilic chemoattractant) in response to C. albicans in 
vitro requires TNF-α.[6] Therefore, TNF probably stimulates recruitment of polymorphonuclear 
leukocytes and, moreover, enhances phagocytic activity and oxidative burst during candida infection. 
[48,6] Concerning immunity to Candida, TNF-receptor 1 signaling has been shown to be the principal 
mediator of TNF-α stimulation and is likely to mediate the neutrophilic augmentation of fungus 
phagocytosis and elimination.[6,48] 
 
TNF-α’s role in defense against Leishmania 
Leishmania, an intracellular parasite, is also controlled by the immune system in a TNF-dependent 
manner. [49,50] While there are many Leshmania species, TNF seems to play a role transversal to them; 
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nonetheless, it also appears that different regulation mechanisms might be involved in the protective 
immune response against the different species.[51] Upon infection, a specific immune response is 
mounted after the transition of dendritic cells from peripheral tissue to draining lymph nodes, and the 
presence of TNF at the site of challenge is essential to achieve an effective migration of sufficient number 
of antigen-presenting dendritic cells. [50] After that, the T-cells are activated and produce IFN-ƴ, which 
in turn is synergistically supported by TNF-α, and drives macrophages to upregulate the enzyme iNOS to 
produce large amounts of the effector molecule, nitric oxide, essential for the resolution of Leishmania 
major infections in vivo.[49] For example, after infection with a Leishmania major substrain, TNF-
negative mice were unable to mount a protective adaptive immune response. [50] In one study, the 
authors correlate this deficient protective response with: a reduction in the dermal infiltrate of 
inflammatory cells and a consequent diminution of inflammatory cytokines (such as IFN-ƴ); a lack of 
upregulation of chemokine CCL21, known to be involved in proinflammatory-cells migration (namely the 
orchestration of mature CCR7
+ 
dendritic-cells migration to draining lymph nodes). [50] The authors 
hypothesize this findings could be related to a previously found involvement of TNF-α in dendritic cells 
maturation and, thus, CCR7 expression. Therefore, TNF and CCL21 locally expressed in the skin would 
enhance specific antigen presentation by increasing the number of dendritic cells that migrate to local 
lymph nodes.[50] In another study, with dendritic-cells cultured in vitro, the authors found them to have a 
differential activation, distinguishing cells infected by Leishmania braziliensis from bystander dendritic 
cells. In fact, bystander-cells were shown to be activated in this context (contrary to the infected cells), 
producing IL-12, TNF-α and class II CD80 and CD86 surface markers, and thus being capable of 
initiating a T-cell response. These findings were replicated with other Leishmania species (major and 
mexicana). [51] The inhibition of TNF prevented bystander dendritic cells’ activation; therefore, TNF 
was shown to be essential for their activation to the mature form, which in turn permits antigen 
presentation and T-cell activation.  [51]  However, while the lack of T-cell activation seems to be a 
suitable mechanism to prevent Leishmania immune resistance, a recent work with mice models infected 
with Leishmania major demonstrated that, in the presence of a strong T-helper 1 response, along with 
significantly elevated IFN-ƴ expression in lymph nodes of TNF-null mice, and relatively strong 
expression of iNOS in the draining lymph nodes, TNF’s absence prevented an effective immune 
response. [49] In this study, TNF-receptor 1 was proven the most important receptor in the protective 
immune response, while wild-type mice and mice expressing only the membrane-TNF form, controlled 
the infection and showed a comparable course. On the other hand, TNF-receptor 2-deficient mice 
developed a large skin lesion, similarly to what was evidenced by TNF-receptor 1-deficient mice; 
nevertheless, as opposed to the latter group, they were ultimately able to control the infection. [49] 
 
Conclusion 
Biological treatment with anti-TNF-α drugs seems to be related to the emergence of infectious 
diseases. After the introduction of these drugs, multiple reports have emerged of infections concomitant 
to the anti-TNF-α therapy.[52] Nonetheless, so far, tuberculosis was the only infection shown to present a 
high correlation with anti-TNF-α therapy, and the existence of a cause-effect for other infections is still 
dubious. [53] Additionally, there are many confounding factors potentially influencing these 
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observations: generally, the patients taking these drugs are already immunologically suppressed with 
other agents; moreover, their own pathology could influence the immunological system, and thus the 
immune control of infections.[54] Furthermore, it is hard to find a control population for these 
individuals, as the emergence of infections is greatly related to the patient’s background: if an infectious 
disease has a low frequency in a specific population, individuals from that population (including the 
patients with neutralized-TNF-α) will consequently have a low probability of catching said infection; thus 
making it difficult to prove statistically significant increases in infections in patients treated with anti-
TNF-α. 
Our research has returned a significant amount of articles reporting various infections in patients 
taking TNF-α suppressing drugs. In fact, respiratory infections are amongst the most common reported 
adverse effects of TNF-α’s inhibitory therapy; virus like Influenza and Adenovirus may be frequently 
involved as well. [9] Nonetheless, although most results show a higher incidence of infections among 
these patients, it does not seem to be a clear consensus in literature regarding the existence of a significant 
increase in susceptibility to infection as a consequence of anti-TNF-α therapy. Despite that, doctors 
usually approach this problem in clinical practice, and several guidelines include recommendations to 
apply preventive measures prior to initiating a patient on anti-TNFα therapy, namely screening for 
tuberculosis and HBV, along with subsequent treatment if necessary.[55] 
Ever since TNF-α was made available, many experimental studies have correlated this cytokine with 
immune protection against an array of pathogens. Nevertheless, considering clinical studies’ limitations, 
they cannot provide definite evidence that the increasing incidence of infections results from TNF-α’s 
neutralization; experimental studies on this subject are therefore essential to gather further evidence on 
the importance of TNF-α in immune protection. However, the experimental models used so far in this 
context present some limitations when extrapolating the findings to human physiology. Nonetheless, 
experiments show that TNF’s presence is strongly correlated with the inhibition of some microorganisms; 
furthermore, TNF’s inhibition was associated with an increased burden of microorganisms; these findings 
suggest that this cytokine is very important for the regulation of the immune system and, additionally, that 
it is likely of great importance in controlling pathogens in human hosts. Supporting these hypothesis, 
several studies using human subjects evidenced that susceptibility to different infections is significantly 
influenced by whether the individual carries a TNF-α polymorphism.  
The authors of this paper proposed themselves to collect the experimental evidence in favor of TNF-
α’s role in infection control and to comprehensibly summarize its pathways and biological actions. 
However, in view of the large amount of information collected on the subject over the last decades, and 
the fact that, for methodological reasons, the authors only considered works published after 1995, it is 
possible that many important works were excluded, and this article may thus reflect only a fraction of the 
information already established on TNF-α’s functions in infection control. Nevertheless, this review 
includes information concerning several experimental models in which TNF-α exerts an essential role, 
and the authors attempted to list all the pathogens in regard to which there seemed to be evidence 
supporting TNF-α’s intervention. 
Nonetheless, there is still much to be clarified regarding TNF-α’s mechanisms and functions. In fact, 
its signaling appears to result in hundreds of different outcomes, probably dependent of cellular factors 
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and kinetic characteristics; additionally, in some cases, TNF seems to favor the proliferation of 
microorganisms, rather than controlling the infection (e.g. in HIV infection).[56] Moreover, the pathways 
through which it controls infections and whether they are cytotoxic, are not yet fully understood.  
The comprehension on how TNF exerts its effects could be of great value, potentially offering new 
ways to improve infections’ control; furthermore, assuming TNF’s inhibition does increase susceptibility 
to infections, this knowledge could be helpful in preventing infections in individuals taking anti-TNF-α 
drugs. 
Conflict of Interest: The authors declare that they have no conflict of interest. 
Ethical approval: This article does not contain any studies with human participants or animals 
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 Tables 
 All tables are to be numbered using Arabic numerals. 
 Tables should always be cited in text in consecutive numerical order.  
 For each table, please supply a table caption (title) explaining the components of the table. 
 Identify any previously published material by giving the original source in the form of a reference at 
the end of the table caption. 
 Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance 
values and other statistical data) and included beneath the table body. 
General remark 
Please use graphs instead of tables, whenever possible. 
 
Artwork and Illustrations Guidelines 
Electronic Figure Submission 
 Supply all figures electronically. 
 Indicate what graphics program was used to create the artwork. 
 For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MSOffice files 
are also acceptable. 
 Vector graphics containing fonts must have the fonts embedded in the files. 
 Name your figure files with "Fig" and the figure number, e.g., Fig1.eps. 
Line Art 
 
 Definition: Black and white graphic with no shading. 
 Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible 
at final size. 
 All lines should be at least 0.1 mm (0.3 pt) wide. 
 Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 
dpi. 
 Vector graphics containing fonts must have the fonts embedded in the files. 
Halftone Art 
 
 Definition: Photographs, drawings, or paintings with fine shading, etc. 
 If any magnification is used in the photographs, indicate this by using scale bars within the figures 
themselves. 
 Halftones should have a minimum resolution of 300 dpi. 
Combination Art 
  Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive 
lettering, color diagrams, etc. 
 Combination artwork should have a minimum resolution of 600 dpi. 
Color Art 
 Color art is free of charge for online publication. 
 If black and white will be shown in the print version, make sure that the main information will still be 
visible. Many colors are not distinguishable from one another when converted to black and white. A 
simple way to check this is to make a xerographic copy to see if the necessary distinctions between the 
different colors are still apparent. 
 If the figures will be printed in black and white, do not refer to color in the captions. 
 Color illustrations should be submitted as RGB (8 bits per channel). 
Figure Lettering 
 To add lettering, it is best to use Helvetica or Arial (sans serif fonts). 
 Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 
pt). 
 Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 
20-pt type for the axis label. 
 Avoid effects such as shading, outline letters, etc. 
 Do not include titles or captions within your illustrations. 
Figure Numbering 
 All figures are to be numbered using Arabic numerals. 
 Figures should always be cited in text in consecutive numerical order. 
 Figure parts should be denoted by lowercase letters (a, b, c, etc.). 
 If an appendix appears in your article and it contains one or more figures, continue the consecutive 
numbering of the main text. Do not number the appendix figures, 
"A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) should, however, 
be numbered separately. 
Figure Captions 
 Each figure should have a concise caption describing accurately what the figure depicts. Include the 
captions in the text file of the manuscript, not in the figure file. 
 Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type. 
 No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the 
caption. 
 Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate 
points in graphs. 
 Identify previously published material by giving the original source in the form of a reference citation 
at the end of the figure caption. 
Figure Placement and Size 
 Figures should be submitted separately from the text, if possible. 
 When preparing your figures, size figures to fit in the column width. 
 For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 
234 mm. 
 For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not higher than 
198 mm. 
Permissions 
If you include figures that have already been published elsewhere, you must obtain permission from the 
copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant 
electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive 
these permissions. In such cases, material from other sources should be used. 
Accessibility 
In order to give people of all abilities and disabilities access to the content of your figures, please make sure 
that 
 All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-
Braille hardware) 
 Patterns are used instead of or in addition to colors for conveying information (colorblind users would 
then be able to distinguish the visual elements) 
 Any figure lettering has a contrast ratio of at least 4.5:1 
 
Electronic Supplementary Material 
Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to 
be published online along with an article or a book chapter. This feature can add dimension to the author's 
article, as certain information cannot be printed or is more convenient in electronic form. 
Submission 
 Supply all supplementary material in standard file formats. 
 Please include in each file the following information: article title, journal name, author names; 
affiliation and e-mail address of the corresponding author. 
 To accommodate user downloads, please keep in mind that larger-sized files may require very long 
download times and that some users may experience other problems during downloading. 
Audio, Video, and Animations 
 Aspect ratio: 16:9 or 4:3 
 Maximum file size: 25 GB 
 Minimum video duration: 1 sec  
 Supported file formats: avi, wmv, mp4, mov, m2p, mp2, mpg, mpeg, flv, mxf, mts, m4v, 3gp 
Text and Presentations 
 Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability. 
 A collection of figures may also be combined in a PDF file. 
Spreadsheets 
 Spreadsheets should be converted to PDF if no interaction with the data is intended. 
 If the readers should be encouraged to make their own calculations, spreadsheets should be submitted 
as .xls files (MS Excel). 
Specialized Formats 
 Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can 
also be supplied. 
Collecting Multiple Files 
 It is possible to collect multiple files in a .zip or .gz file. 
Numbering 
 If supplying any supplementary material, the text must make specific mention of the material as a 
citation, similar to that of figures and tables. 
 Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online 
Resource 3)", “... additional data are given in Online Resource 4”. 
 Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”. 
Captions 
 For each supplementary material, please supply a concise caption describing the content of the file.  
Processing of supplementary files 
 Electronic supplementary material will be published as received from the author without any 
conversion, editing, or reformatting.  
Accessibility 
In order to give people of all abilities and disabilities access to the content of your supplementary files, please 
make sure that  
 The manuscript contains a descriptive caption for each supplementary material 
 Video files do not contain anything that flashes more than three times per second (so that users prone 
to seizures caused by such effects are not put at risk) 
 
Ethical Responsibilities of Authors 
This journal is committed to upholding the integrity of the scientific record. As a member of the Committee on 
Publication Ethics (COPE) the journal will follow the COPE guidelines on how to deal with potential acts of 
misconduct.  
Authors should refrain from misrepresenting research results which could damage the trust in the journal, the 
professionalism of scientific authorship, and ultimately the entire scientific endeavour. Maintaining integrity of 
the research and its presentation can be achieved by following the rules of good scientific practice, which 
include: 
 The manuscript has not been submitted to more than one journal for simultaneous consideration.  
 The manuscript has not been published previously (partly or in full), unless the new work concerns an 
expansion of previous work (please provide transparency on the re-use of material to avoid the hint of 
text-recycling (“self-plagiarism”)). 
 A single study is not split up into several parts to increase the quantity of submissions and submitted 
to various journals or to one journal over time (e.g. “salami-publishing”). 
 No data have been fabricated or manipulated (including images) to support your conclusions 
 No data, text, or theories by others are presented as if they were the author’s own (“plagiarism”). 
Proper acknowledgements to other works must be given (this includes material that is closely copied 
(near verbatim), summarized and/or paraphrased), quotation marks are used for verbatim copying of 
material, and permissions are secured for material that is copyrighted.  
Important note: the journal may use software to screen for plagiarism. 
 Consent to submit has been received explicitly from all co-authors, as well as from the responsible 
authorities - tacitly or explicitly - at the institute/organization where the work has been carried out, 
before the work is submitted. 
 Authors whose names appear on the submission have contributed sufficiently to the scientific work 
and therefore share collective responsibility and accountability for the results. 
In addition: 
 Changes of authorship or in the order of authors are not accepted after acceptance of a manuscript. 
 Requesting to add or delete authors at revision stage, proof stage, or after publication is a serious matter 
and may be considered when justifiably warranted. Justification for changes in authorship must be 
compelling and may be considered only after receipt of written approval from all authors and a 
convincing, detailed explanation about the role/deletion of the new/deleted author. In case of changes 
at revision stage, a letter must accompany the revised manuscript. In case of changes after acceptance 
or publication, the request and documentation must be sent via the Publisher to the Editor-in-Chief. In 
all cases, further documentation may be required to support your request. The decision on accepting 
the change rests with the Editor-in-Chief of the journal and may be turned down. Therefore authors 
are strongly advised to ensure the correct author group, corresponding author, and order of authors at 
submission. 
 Upon request authors should be prepared to send relevant documentation or data in order to verify the 
validity of the results. This could be in the form of raw data, samples, records, etc. 
If there is a suspicion of misconduct, the journal will carry out an investigation following the COPE guidelines. 
If, after investigation, the allegation seems to raise valid concerns, the accused author will be contacted and 
given an opportunity to address the issue. If misconduct has been established beyond reasonable doubt, this 
may result in the Editor-in-Chief’s implementation of the following measures, including, but not limited to:  
 If the article is still under consideration, it may be rejected and returned to the author.  
 If the article has already been published online, depending on the nature and severity of the infraction, 
either an erratum will be placed with the article or in severe cases complete retraction of the article 
will occur. The reason must be given in the published erratum or retraction note.  
 The author’s institution may be informed. 
 
Compliance with Ethical Standards 
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and 
professional conduct have been followed, authors should include information regarding sources of funding, 
potential conflicts of interest (financial or non-financial), informed consent if the research involved human 
participants, and a statement on welfare of animals if the research involved animals. 
Authors should include the following statements (if applicable) in a separate section entitled “Compliance with 
Ethical Standards” when submitting a paper: 
 Disclosure of potential conflicts of interest  
 Research involving Human Participants and/or Animals 
 Informed consent  
Please note that standards could vary slightly per journal dependent on their peer review policies (i.e. single or 
double blind peer review) as well as per journal subject discipline. Before submitting your article check the 
instructions following this section carefully. 
The corresponding author should be prepared to collect documentation of compliance with ethical standards 
and send if requested during peer review or after publication. 
The Editors reserve the right to reject manuscripts that do not comply with the above-mentioned guidelines. 
The author will be held responsible for false statements or failure to fulfill the above-mentioned guidelines. 
 
Disclosure of potential conflicts of interest 
Authors must disclose all relationships or interests that could have direct or potential influence or impart bias 
on the work. Although an author may not feel there is any conflict, disclosure of relationships and interests 
provides a more complete and transparent process, leading to an accurate and objective assessment of the work. 
Awareness of a real or perceived conflicts of interest is a perspective to which the readers are entitled. This is 
not meant to imply that a financial relationship with an organization that sponsored the research or 
compensation received for consultancy work is inappropriate. Examples of potential conflicts of interests that 
are directly or indirectly related to the research may include but are not limited to the following: 
 Research grants from funding agencies (please give the research funder and the grant number) 
 Honoraria for speaking at symposia 
 Financial support for attending symposia 
 Financial support for educational programs 
 Employment or consultation 
 Support from a project sponsor  
 Position on advisory board or board of directors or other type of management relationships  
 Multiple affiliations 
 Financial relationships, for example equity ownership or investment interest 
 Intellectual property rights (e.g. patents, copyrights and royalties from such rights) 
 Holdings of spouse and/or children that may have financial interest in the work 
In addition, interests that go beyond financial interests and compensation (non-financial interests) that may be 
important to readers should be disclosed. These may include but are not limited to personal relationships or 
competing interests directly or indirectly tied to this research, or professional interests or personal beliefs that 
may influence your research. 
The corresponding author collects the conflict of interest disclosure forms from all authors. In author 
collaborations where formal agreements for representation allow it, it is sufficient for the corresponding author 
to sign the disclosure form on behalf of all authors. Examples of forms can be found 
 here: 
The corresponding author will include a summary statement in the text of the manuscript in a separate section 
before the reference list, that reflects what is recorded in the potential conflict of interest disclosure form(s).  
See below examples of disclosures: 
Funding: This study was funded by X (grant number X). 
Conflict of Interest: Author A has received research grants from Company A. Author B has received a speaker 
honorarium from Company X and owns stock in Company Y. Author C is a member of committee Z.  
If no conflict exists, the authors should state:  
Conflict of Interest: The authors declare that they have no conflict of interest. 
 
Research involving human participants and/or animals 
1) Statement of human rights 
When reporting studies that involve human participants, authors should include a statement that the studies have 
been approved by the appropriate institutional and/or national research ethics committee and have been 
performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its 
later amendments or comparable ethical standards. 
If doubt exists whether the research was conducted in accordance with the 1964 Helsinki Declaration or 
comparable standards, the authors must explain the reasons for their approach, and demonstrate that the 
independent ethics committee or institutional review board explicitly approved the doubtful aspects of the study.  
The following statements should be included in the text before the References section: 
Ethical approval: “All procedures performed in studies involving human participants were in accordance with 
the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.” 
For retrospective studies, please add the following sentence: 
“For this type of study formal consent is not required.” 
2) Statement on the welfare of animals 
The welfare of animals used for research must be respected. When reporting experiments on animals, authors 
should indicate whether the international, national, and/or institutional guidelines for the care and use of animals 
have been followed, and that the studies have been approved by a research ethics committee at the institution 
or practice at which the studies were conducted (where such a committee exists).  
For studies with animals, the following statement should be included in the text before the References section: 
Ethical approval: “All applicable international, national, and/or institutional guidelines for the care and use of 
animals were followed.” 
If applicable (where such a committee exists): “All procedures performed in studies involving animals were in 
accordance with the ethical standards of the institution or practice at which the studies were conducted.” 
If articles do not contain studies with human participants or animals by any of the authors, please select one of 
the following statements: 
“This article does not contain any studies with human participants performed by any of the authors.” 
“This article does not contain any studies with animals performed by any of the authors.” 
“This article does not contain any studies with human participants or animals performed by any of the authors.” 
 
Informed consent 
All individuals have individual rights that are not to be infringed. Individual participants in studies have, for 
example, the right to decide what happens to the (identifiable) personal data gathered, to what they have said 
during a study or an interview, as well as to any photograph that was taken. Hence it is important that all 
participants gave their informed consent in writing prior to inclusion in the study. Identifying details (names, 
dates of birth, identity numbers and other information) of the participants that were studied should not be 
published in written descriptions, photographs, and genetic profiles unless the information is essential for 
scientific purposes and the participant (or parent or guardian if the participant is incapable) gave written 
informed consent for publication. Complete anonymity is difficult to achieve in some cases, and informed 
consent should be obtained if there is any doubt. For example, masking the eye region in photographs of 
participants is inadequate protection of anonymity. If identifying characteristics are altered to protect 
anonymity, such as in genetic profiles, authors should provide assurance that alterations do not distort scientific 
meaning. 
The following statement should be included: 
Informed consent: “Informed consent was obtained from all individual participants included in the study.”  
If identifying information about participants is available in the article, the following statement should be 
included: 
“Additional informed consent was obtained from all individual participants for whom identifying information 
is included in this article.” 
 
After acceptance 
Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s 
web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order 
OpenChoice, offprints, or printing of figures in color.  
Once the Author Query Application has been completed, your article will be processed and you will receive the 
proofs. 
Open Choice  
In addition to the normal publication process (whereby an article is submitted to the journal and access to that 
article is granted to customers who have purchased a subscription), Springer provides an alternative publishing 
option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-
based article, but in addition is made available publicly through Creative Commons Attribution-
NonCommercial 4.0 International License. 
 Springer Open Choice 
Copyright transfer  
Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive 
publication and dissemination rights). This will ensure the widest possible protection and dissemination of 
information under copyright laws.  
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for 
open access, the author(s) agree to publish the article under the Creative Commons Attribution License. 
 Creative Commons Attribution-NonCommercial 4.0 International License 
Offprints 
Offprints can be ordered by the corresponding author. 
Color illustrations 
Online publication of color illustrations is free of charge. For color in the print version, authors will be expected 
to make a contribution towards the extra costs. 
Proof reading 
The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of 
the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and 
authorship, are not allowed without the approval of the Editor. 
After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked 
to the article. 
Online First 
The article will be published online after receipt of the corrected proofs. This is the official first publication 
citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers. 
 
Does Springer provide English language support? 
Manuscripts that are accepted for publication will be checked by our copyeditors for spelling and formal style. 
This may not be sufficient if English is not your native language and substantial editing would be required. In 
that case, you may want to have your manuscript edited by a native speaker prior to submission. A clear and 
concise language will help editors and reviewers concentrate on the scientific content of your paper and thus 
smooth the peer review process. 
The following editing service provides language editing for scientific articles in all areas Springer 
publishes in: 
 Edanz English editing for scientists 
Use of an editing service is neither a requirement nor a guarantee of acceptance for publication. 
Please contact the editing service directly to make arrangements for editing and payment. 
For Authors from China 
文 章在投稿前进行专业的语言润色将对作者的投稿进程有所帮助。作者可自愿选择使用Springer推荐
的编辑服务，使用与否并不作为判断文章是否被录用的依 据。提高文章的语言质量将有助于审稿人理
解文章的内容，通过对学术内容的判断来决定文章的取舍，而不会因为语言问题导致直接退稿。作者
需自行联系 Springer推荐的编辑服务公司，协商编辑事宜。 
 理文编辑 
For Authors from Japan 
ジャーナルに論文を投稿する前に、ネイティブ・スピーカーによる英文校閲を希望されている方に
は、Edanz社をご紹介しています。サービス内容、料金および申込方法など、日本語による詳しい
説明はエダンズグループジャパン株式会社の下記サイトをご覧ください。 
 エダンズグループジャパン 
For Authors from Korea 
영어 논문 투고에 앞서 원어민에게 영문 교정을 받고자 하시는 분들께 Edanz 회사를 소개해 드립니다. 
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신청 방법 등에 대한 자세한 사항은 저희 Edanz Editing Global 웹사이트를 참조해 주시면 
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